» Articles » PMID: 37227598

Understanding the Impact of Bioactive Coating Materials for Human Mesenchymal Stromal Cells and Implications for Manufacturing

Overview
Journal Biotechnol Lett
Date 2023 May 25
PMID 37227598
Authors
Affiliations
Soon will be listed here.
Abstract

Bioactive materials interact with cells and modulate their characteristics which enable the generation of cell-based products with desired specifications. However, their evaluation and impact are often overlooked when establishing a cell therapy manufacturing process. In this study, we investigated the role of different surfaces for tissue culture including, untreated polystyrene surface, uncoated Cyclic Olefin Polymer (COP) and COP coated with collagen and recombinant fibronectin. It was observed that human mesenchymal stromal cells (hMSCs) expanded on COP-coated plates with different bioactive materials resulted in improved cell growth kinetics compared to traditional polystyrene plates and non-coated COP plates. The doubling time obtained was 2.78 and 3.02 days for hMSC seeded in COP plates coated with collagen type I and recombinant fibronectin respectively, and 4.64 days for cells plated in standard polystyrene treated plates. Metabolite analysis reinforced the findings of the growth kinetic studies, specifically that cells cultured on COP plates coated with collagen I and fibronectin exhibited improved growth as evidenced by a higher lactate production rate (9.38 × 10 and 9.67 × 10 pmol/cell/day, respectively) compared to cells from the polystyrene group (5.86 × 10 pmol/cell/day). This study demonstrated that COP is an effective alternative to polystyrene-treated plates when coated with bioactive materials such as collagen and fibronectin, however COP-treated plates without additional coatings were found not to be sufficient to support cell growth. These findings demonstrate the key role biomaterials play in the cell manufacturing process and the importance of optimising this selection.

Citing Articles

Profiling of collagen and extracellular matrix deposition from cell culture using in vitro ExtraCellular matrix mass spectrometry imaging (ivECM-MSI).

Zambrzycki S, Saberi S, Biggs R, Eskandari N, Delisi D, Taylor H Matrix Biol Plus. 2024; 24:100161.

PMID: 39435160 PMC: 11492733. DOI: 10.1016/j.mbplus.2024.100161.


Scalable manufacturing of gene-modified human mesenchymal stromal cells with microcarriers in spinner flasks.

Couto P, Stibbs D, Rotondi M, Takeuchi Y, Rafiq Q Appl Microbiol Biotechnol. 2023; 107(18):5669-5685.

PMID: 37470820 PMC: 10439856. DOI: 10.1007/s00253-023-12634-w.

References
1.
Singh P, Schwarzbauer J . Fibronectin and stem cell differentiation - lessons from chondrogenesis. J Cell Sci. 2012; 125(Pt 16):3703-12. PMC: 3462078. DOI: 10.1242/jcs.095786. View

2.
Oikonomopoulos A, van Deen W, Manansala A, Lacey P, Tomakili T, Ziman A . Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep. 2015; 5:16570. PMC: 4643287. DOI: 10.1038/srep16570. View

3.
Heino J . The collagen family members as cell adhesion proteins. Bioessays. 2007; 29(10):1001-10. DOI: 10.1002/bies.20636. View

4.
Rafiq Q, Hanga M, Heathman T, Coopman K, Nienow A, Williams D . Process development of human multipotent stromal cell microcarrier culture using an automated high-throughput microbioreactor. Biotechnol Bioeng. 2017; 114(10):2253-2266. PMC: 5615370. DOI: 10.1002/bit.26359. View

5.
Rafiq Q, Coopman K, Nienow A, Hewitt C . Systematic microcarrier screening and agitated culture conditions improves human mesenchymal stem cell yield in bioreactors. Biotechnol J. 2015; 11(4):473-86. PMC: 4991290. DOI: 10.1002/biot.201400862. View